---
title: Influence of Daylong Glycemia on Detraining Induced Metabolic Changes
nct_id: NCT02321033
overall_status: COMPLETED
phase: NA
sponsor: University of Hohenheim
study_type: INTERVENTIONAL
primary_condition: Healthy
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02321033.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02321033"
ct_last_update_post_date: 2015-11-18
last_seen_at: "2026-05-12T07:29:21.113Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Influence of Daylong Glycemia on Detraining Induced Metabolic Changes

**Official Title:** Einfluss Der Postprandialen Glykämie Auf Inaktivitäts-induzierte Veränderungen im Stoffwechsel

**NCT ID:** [NCT02321033](https://clinicaltrials.gov/study/NCT02321033)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 16
- **Lead Sponsor:** University of Hohenheim
- **Conditions:** Healthy
- **Start Date:** 2014-08
- **Completion Date:** 2015-09
- **CT.gov Last Update:** 2015-11-18

## Brief Summary

Aim of the study is to investigate the impact of glycemic index (provided as soft drinks) on changes in insulin sensitivity, metabolic flexibility, and arterial stiffness in response to detraining.

The investigators hypothesize that low glycemic soft drinks decrease the detraining-induced impairment of insulin sensitivity, metabolic flexibility and arterial stiffness.

## Detailed Description

The duration of the study is 7 weeks: two x 2 weeks intervention (phase A and phase B) with 3 weeks washout phase inbetween. Each 2-week intervention phase consists of an active week followed by an inactive week.

in phase A subjects consume high GI (maltodextrin and sucrose) soft drinks during the inactive week. In phase B subjects consume a low GI soft drink (palatinose) during the inactive week.

subjects were randomly assigned to either start with phase A or with phase B (cross over design).

During the whole study duration all food is provided (55% CHO, 30% fat, 15% protein)

Physical activity will be assessed by a step counter (active phase 7000-10000 steps/d and inactive phase 3000-4000 steps/d).

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 35 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* normal weight men,
* age 18-35 y,
* active life style,
* \> 300 min sports/week

Exclusion Criteria:

* food allergies,
* regular use of medication,
* smoking,
* chronic disease,
* vegan/vegetarian diet
```

## Arms

- **low glycemic index** (EXPERIMENTAL) — palatinose in soft drinks
- **high glycemic index** (EXPERIMENTAL) — sucrose plus maltodextrin in soft drinks

## Interventions

- **soft drinks** (DIETARY_SUPPLEMENT) — soft drinks with palatinose and maltodextrin

## Primary Outcomes

- **Influence of GI on inactivity-induced changes in insulin sensitivity as measured by an OGTT** _(time frame: the difference between the end of each 1 week activity phase (day 7 vs. day 14, low vs. high physical activity) is compared between high GI and low GI intervention)_ — Influence of GI (glycemic index) on detraining-induced changes (difference between the end of high activity and low activity phases) in insulin sensitivity Insulin sensitivity is assessed by HOMA and Matsuda indices

## Secondary Outcomes

- **Influence of GI on inactivity-induced changes in metabolic flexibility as measured by indirect calorimetry (RER, respiratory exchange ratio)** _(time frame: the difference between the end of each 1 week activity phase (day 7 vs. day 14) is compared between high GI and low GI intervention)_

## Locations (1)

- Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany

## Recent Field Changes (last 30 days)

- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.institute of nutritional medicine, university of hohenheim|stuttgart||germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02321033.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02321033*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*